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The immediate-early (IE) BZLF1 gene of Epstein-Barr virus (EBV) regulates the switch between latent and lytic infection
by EBV. We previously showed that the cellular transcription factor ZEB1 binds to a sequence element, ZV, located at nt
 17 to 12 relative to the transcription initiation site of the BZLF1 promoter, Zp, repressing transcription from Zp in a
transient transfection assay. Here, we report the phenotype in the context of a whole EBV genome of a variant of EBV
strain B95.8 containing a 2-bp substitution mutation in the ZV element of Zp that reduced, but did not eliminate, ZEB1
binding to Zp. Strikingly, epithelial 293 cells latently infected with the EBV ZV mutant spontaneously produced IE-,
early-, and late-gene products and infectious virus, while wild-type (WT)-infected 293 cells did not and have never been
reported to do so. Furthermore, treatment with the chemical inducers sodium butyrate and 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) led to an additional order-of-magnitude production of infectious virus in the ZV mutant–
infected 293 cells, but still no virus in the WT-infected 293 cells. Similarly, ZV mutant–infected Burkitt’s lymphoma
BJAB cells accumulated at least 10-fold more EBV IE mRNAs than did WT-infected BJAB cells, with TPA or sodium
butyrate treatment leading to an additional 5- to 10-fold accumulation of EBV IE mRNAs in the ZV mutant–infected
cells. Thus, we conclude that ZEB1 binding to Zp plays a central role in regulating the latent-lytic switch in EBV-infected
epithelial and B cells, suggesting ZEB1 as a target for lytic-induction therapies in EBV-associated malignancies.
Citation: Yu X, Wang Z, Mertz JE (2007) ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog 3(12): e194. doi:10.1371/journal.ppat.0030194
Introduction
Epstein-Barr virus (EBV) is a human gamma herpesvirus
estimated to infect 90% of the world’s population. It is a
causative agent of or associated with infectious mononucleo-
sis and several B-cell and epithelial-cell cancers including
Burkitt’s lymphoma (BL), Hodgkin’s disease, nasopharyngeal
carcinoma, and some gastric carcinomas (reviewed in [1]).
EBV can infect and immortalize primary B lymphocytes,
leading to a latent form of infection in which its genome is
maintained as an episome replicating via its viral origin of
replication, ori-P, in synchrony with its host cell’s DNA. EBV
can also infect epithelial cells, leading to a latent or lytic form
of infection depending upon the speciﬁc cell type and state of
cellular differentiation. Only a few of the ;100 genes in EBV
are expressed during latency unless reactivation occurs,
leading to lytic replication with production of infectious
virus (reviewed in [2]).
Understanding regulation of the switch between latency
and lytic replication is a central problem in herpes virology.
EBV provides an excellent system to address this problem.
Reactivation of EBV out of latency is usually initiated via
activating expression of the immediate-early (IE) BZLF1 gene
[3] which encodes a sequence-speciﬁc DNA-binding protein,
Zta (also called Z, Zebra, and EB1), a member of the bZIP
family of leucine-zipper transactivators. The activities of Zta
include directly participating in EBV replication via binding
to the viral DNA origin of lytic replication, ori-Lyt, down-
regulating the latency-associated promoters Cp and Wp, and
serving as a transcriptional transactivator of its own
promoter, other IE and early (E) viral promoters including
the BRLF1 promoter, Rp, and several cellular promoters. The
BRLF1 gene encodes a second viral transactivator, Rta (also
called R). Acting together, Zta and Rta play multiple roles in
lytic replication of EBV. While highly quiescent during
latency, expression of the BZLF1 promoter, Zp, can be
activated in some cells by treatment with various inducers
including phorbol esters such as 12-O-tetradecanoyl-phorbol-
13-acetate (TPA), calcium ionophores such as ionomycin,
sodium butyrate, transforming growth factor b (TGF-b) and
anti-immunoglobulins (anti-Igs) (reviewed in [4]).
Transcription of the BZLF1 gene can be initiated from
either its proximal promoter, Zp, or the more distal
promoter, Rp. However, most Zta protein is synthesized from
mRNA initiated at Zp. The cis-acting elements of Zp sufﬁcient
for both basal and induced activity lie within the nucleotide
(nt)  221 to þ12 region relative to the promoter’s tran-
scription initiation site (reviewed in [4,5]) (Figure 1). Four
AT-rich motifs, named ZIA through ZID, can bind the
transcription factors Sp1, Sp3, and the myocyte enhancer
factor 2D (MEF2D) [6,7]. ZII is a CRE-like motif that binds
CREB, ATF family members, C/EBPs, and the AP-1 family of
transcription factors [8–11]. ZIII contains multiple binding
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Smads have also been identiﬁed [13].
Three elements involved in transcriptional silencing have
also been identiﬁed within the nt  221 to þ12 region of Zp:
ZIIR [14], HIe [15], and ZV [16]. Other silencing elements,
termed ZIV [17] and HIa-HId [15], lie within the nt  551 to
 222 region of Zp. We have identiﬁed ZEB1 (also called dEF1,
TCF8, AREB6, ZFHEP, NIL-2A, ZFHX1A, and BZP) as the
main cellular factor in B-lymphocytes repressing transcrip-
tion from Zp via binding the ZV element [18]. While
repressors that recognize silencing elements upstream of nt
 221 have been identiﬁed [19,20], ZEB1 and MEF2D are the
only ones known to bind functionally within the nt  221 to
þ12 region of Zp.
Here, we report the effects of a 2-bp substitution mutation
in the Zp ZV element in the context of a whole EBV genome.
Quite strikingly, this ZV mutant (mt) of EBV spontaneously
reactivated out of latently infected human epithelial 293 cells
into lytic replication with production of infectious virus
under conditions in which its WT parental virus never does.
Burkitt’s lymphoma BJAB cells latently infected with the ZV
mutant also exhibited spontaneous synthesis of Zta mRNA
under culture conditions in which WT-infected BJAB cells
did not. Furthermore, treatment of the ZV mutant-infected
BJAB cells with TPA led to high-level synthesis of Zta and Rta
mRNAs while these IE viral genes remained silent in the WT-
infected BJAB cells. Others have previously reported that
ZEB1 is also a transcriptional repressor of the cellular E-
cadherin promoter [21], with reduction in E-cadherin
expression linked to tumor invasion, metastasis, and unfav-
orable prognosis [22]. ZEB1 represses by functioning as a
molecular beacon for recruitment to promoters of CoREST-
CtBP co-repressor complexes [23]. Taken together, we
conclude that ZEB1 plays a central role in maintaining EBV
infection in a latent form in both epithelial and B cells and,
thus, is an excellent target for lytic-induction therapy for
EBV-associated malignancies.
Results
Isolation of Cell Lines Latently Infected with a ZV Mutant
of EBV
Substitution mutations in the Zp ZV element of either (i) A
to C at nt  12 or (ii) A to C at nt  12 plus T to C at nt  13
relative to the Zp transcription initiation site were shown
previously to partially relieve both (i) binding of ZEB1 and (ii)
repression of Zp by ZEB1 in transient transfection assays
[16,18] and mini-EBV replicons [24]. To examine the role of
the Zp ZV element in establishing and maintaining EBV in a
latent form of infection, we introduced this 12C,  13C 2-bp
substitution mutation in the ZV element (ZVmt) into an
intact EBV genome using a bacmid, p2089. Plasmid p2089
contains a wild-type copy of the complete genome of the
B95.8 strain of EBV along with a mini F plasmid and
Figure 1. BZLF1 Promoter
(A) Schematic indicating the cis-acting regulatory elements present in the nt 221 throughþ40 region of Zp. Rectangles along Zp indicate approximate
locations of known regulatory elements; their trans-acting factors are indicated above them. ZEB1 concurrently binds via its two zinc-finger domains to
the two cis-acting elements ZV and ZV’. The transcription initiation site is indicated by a rightward arrow.
(B) Nucleotide sequence of the nt  30 to þ20 region of Zp. The ZV and ZV’ elements are boxed. The 2-bp substitution mutation in the ZV element
shown below the sequence was introduced here into the EBV genome.
doi:10.1371/journal.ppat.0030194.g001
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Author Summary
Ninety percent of people in the world become infected with
Epstein-Barr virus (EBV). The virus can infect both epithelial and B
cells, either making more virus and killing the cell or establishing a
latent form of infection where it is stably maintained in the host. EBV
infection is associated with the development of some types of
cancer. We show here that a mere 2-bp substitution mutation in the
silencer element, ZV, of the promoter of EBV’s immediate-early
BZLF1 gene in the context of a whole EBV genome can lead to
spontaneous reactivation of EBV out of latency into lytic replication,
with production of infectious virus in some cells. The presence of the
mutation also (i) made the virus more responsive to reactivation
following treatment with chemical inducers, and (ii) disrupted
binding of a cellular transcriptional repressor protein, ZEB1, to the
BZLF1 promoter. Our work suggests a method to kill EBV-infected
cancer cells by treating them with agents that lower the repressor
activity of ZEB1. It also suggests one may be able to generate a
vaccine against EBV infection using a constitutively lytic EBV strain
made by knocking out the silencer elements of the BZLF1 promoter.expression cassettes for hygromycin phosphotransferase,
green ﬂuorescence protein (GFP), and chloramphenicol
acetyl transferase [25]. The parental p2089-WT and two
completely independent isolates of p2089-ZVmt were trans-
fected in parallel into 293 cells, and the cells were grown
thereafter in the presence of hygromycin. Numerous hy-
gromycin-resistant, GFP-positive colonies were visible within
3–4 weeks after transfection with either p2089-WT or p2089-
ZVmt. Independent clones of latently infected cells were
grown out into cell lines. Virus stocks of WT and ZVmt EBV
were generated by co-transfection of these cell lines with
pCMV-BZLF1 and p2670, plasmids expressing the EBV-
encoded proteins Zta and glycoprotein 110, respectively, to
induce lytic replication and production of infectious virus
[26]. The titers of these virus stocks were determined by a Raji
cell assay [27]. Multiple independent cell lines containing
p2089-WT or p2089-ZVmt which consistently yielded infec-
tious virus with titers of 10
4 to 10
5 green Raji units (GRUs)
per ml of medium following induction were chosen for
further analysis.
To determine whether extraneous mutations might have
arisen during either construction of the mutant plasmid or
establishment and passage of the cell lines, p2089 DNA was
extracted from each cell line. First, the nt 600 toþ500 region
of the BZLF1 gene in each plasmid was PCR-ampliﬁed and
resequenced to make sure no extraneous mutations were
present in the promoter region of this gene; only the
expected  12C,  13C substitution mutations were observed.
Second, Southern blot analyses of BamHI-digested plasmid
DNA were performed with a variety of EBV DNA probes; no
gross alterations in the EBV genomes were observed (e.g.,
Figure 2A; data not shown). The p2089 DNAs rescued from
these cell lines were also digested with EcoRI, SalI, and HindIII
restriction endonuclease; again, no differences were observed
Figure 2. Presence of EBV DNA, mRNAs, and Proteins in the Latently Infected 293 Cell Lines Studied Here
(A) Southern blot analyses of the BamHI DNA fragments B, K, R, and Z of the p2089 DNAs isolated from the indicated WT- and ZV mutant-infected 293
cell lines. The locations of these BamHI fragments are indicated on the right.
(B) Mutation in the Zp ZV element leads to increased accumulation of Zta and Rta mRNA in latently infected 293 cell lines. Northern blot analyses were
performed to detect the steady-state levels of Zta and Rta mRNAs present in the WT- and ZVmt-infected 293 cell lines. The bands corresponding to Rta,
Zta, and b-actin mRNAs are indicated on the right. Rta’ corresponds to the 4-kb, amino-terminally unspliced form of Rta mRNA. The size markers
indicated on the left consisted of an RNA ladder (Invitrogen) run in the same gel.
(C) Mutation of the Zp ZV element leads to increased synthesis of the EBV Zta, Rta, and BMRF1 proteins. Immunoblot analyses were performed with
lysates of the indicated cell lines and antisera to Zta, Rta, BMRF1, and b-actin.
doi:10.1371/journal.ppat.0030194.g002
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compared to those of the original p2089 DNA (data not
shown). Third, we also constructed a WT revertant, p2089-
ZVmtRev, by introducing back into p2089-ZVmt DNA the
original  12A and  13T sequence of Zp and isolated and
extensively characterized three independent 293 cell lines
latently infected with p2089-ZVmtRev. The phenotype of this
revertant was found to be indistinguishable from that of the
original p2089-WT in all assays performed on the latently
infected 293 cells (see below). Thus, the EBV genomes present
in these cell lines probably do not differ in any signiﬁcant way
from the B95.8 strain of EBV except for the 2-bp substitution
mutation in the ZV element of Zp.
Three independent lines each of WT-, ZVmt-, and ZVmtRev-
infected 293 cells were chosen for further detailed study. Two
of the ZVmt-infected 293 cell lines were grown out from
independent clones derived from cells transfected with one
isolate of p2089-ZVmt DNA; the third was derived from cells
transfected with p2089-ZVmt DNA obtained from a second,
completely independent mutagenesis of p2089-WT DNA.
Likewise, one of the three WT-infected 293 cell lines was the
one originally described by Hammerschmidt and colleagues
[25]. The other two were independent clones isolated from 293
cells transfected by us with p2089-WT DNA processed in
parallel with the p2089-ZVmt DNAs constructed here.
Spontaneous Reactivation of ZV Mutant EBV
293 cells latently infected with the B95.8 strain of EBV
never spontaneously produce infectious virus because ex-
pression of the BZLF1 and BRLF1 genes is strongly repressed
[28] (M. Altmann and W. Hammerschmidt, personal commu-
nication). Only one laboratory has reported observing WT-
infected 293 cells spontaneously producing EBV [29]; even in
this case, only 2% of over 250 clones examined produced any
EBV, and the cells had been infected with the Akata strain of
EBV, not the B95.8 strain. As expected, we, too, failed to
detect expression of the EBV IE, E, or late (L) genes in any of
our WT-infected 293 cell lines (Figures 2B, 2C, and 3).
Strikingly, both Zta and Rta mRNAs were readily detected in
all three ZVmt-infected 293 cell lines, present at levels at least
20-fold higher than in the WT-infected 293 cell lines (Figure
2B, lanes 4–6 vs. lanes 1–3). Immunoblot analyses conﬁrmed
expression of the IE genes, with each of the ZVmt-infected
cell lines containing at least 30-fold more Zta, Rta, and
BMRF1 protein than the WT- and ZVmtRev-infected cell
lines (Figure 2C, lanes 5–7 vs. lanes 2–4 and lanes 8–10).
BMRF1, an EBV E gene product, is only synthesized after Zta
and Rta are present at sufﬁcient levels to induce the later
stages of the EBV lytic replication cycle. Immunoﬂuorescence
staining conﬁrmed that Zta, Rta, and BMRF1 proteins were
abundantly present in approximately 3% of the cells
adhering to the dishes in each of the these three ZVmt-
infected cell lines (Figure 3; data not shown). IFS also
indicated the presence of gp350, a glycoprotein encoded by
a late gene of EBV, in ;1% of the cells (Figure 3; data not
shown). Likely, once any ZVmt-infected cell expressed Zta at a
level detectable in our IFS assay, it was destined to proceed
on through the entire EBV lytic cycle of replication,
eventually dying, detaching from the dish, and, thus, no
longer being measured in our assay; we observed only one-
third as many gp350-positive cells as Zta-positive cells
because the former had fewer hours remaining before they
detached from the dish. Our ﬁnding 3% Zta-positive cells is
not a measurement of the percent of these mutant-infected
Figure 3. Indirect Immunofluorescence Staining (IFS) of 293-WT Cell Line 1 and 293-ZVmt Cell Line 1 for Presence of Zta, Rta, BMRF1, and gp350 Protein
The primary antibodies used are indicated on the left of each row of images. Fields of cells were photographed with different filters to show the total
EBV-positive ones (GFP) versus the subset of those containing the indicated EBV-encoded protein (IFS).
doi:10.1371/journal.ppat.0030194.g003
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spontaneously reactivating at a rate of ;1% per day if one
assumes the time from reactivation of the BZLF1 promoter to
cell death was ;3 days. In contrast, we failed to detect any
Zta-, Rta-, BMRF1-, or gp350-positive cells in any of the three
WT-infected and three ZVmtRev-infected cell lines (Figure 3;
data not shown). Thus, the 2-bp substitution mutation in the
ZV element of Zp led to greatly increased expression of IE, E,
and L genes of EBV in 293 cells. Therefore, we conclude that
ZV mutant-infected 293 cells spontaneously reactivate into
lytic replication under culture conditions in which 293 cells
infected with the WT B95.8 strain of EBV have never been
reported to do so.
We also assayed the cell lines for production of infectious
virus. Strikingly, all three ZVmt-infected cell lines sponta-
neously produced at least 10
2 green Raji units (GRUs) per ml
of medium (Figure 4A; Table 1). As expected, infectious virus
was not detected in any of the three WT-infected and three
ZVmtRev-infected cell lines unless the cells were transfected
with an expression plasmid encoding Zta or Rta protein (e.g.,
Figure 4A and Table 1; data not shown).
To conﬁrm that the results observed with the Raji cell assay
were truly due to encapsidation of replicated viral DNA into
infectious virion particles, we also examined the termini of
the EBV genomes present in these cell lines. When EBV exists
solely in a latent state as a circular episome, the ends of its
linear viral genome are fused together; cleavage with BamH1
restriction endonuclease generates large terminal EBV DNA
fragments, somewhat heterogenous in size due to variability
in the number of copies of a tandem repeated sequence
present in this region of the EBV genome [30]. However, in
lytically infected cells in which the EBV DNA has been
linearized during packaging into virion particles, cleavage
with BamH1 generates smaller terminal EBV DNA fragments,
also heterogeneous in size. As expected, the EBV DNA
terminal BamHI fragments isolated from the ZVmt-infected
cell lines had sizes consistent with the presence of both
circular and linear EBV genomes (e.g., Figure 4B; data not
shown); no small EBV DNA terminal fragments were detected
with the DNA isolated from the WT-infected cell lines (e.g.,
Figure 4B; data not shown). Therefore, we conclude that
presence of the 2-bp mutation in the Zp ZV element led not
only to derepression of Zp, but also to the entire subsequent
series of events in the EBV lytic replication cycle necessary
for production of infectious virus.
Effects of Inducers on Reactivation Frequency
Transfection of cells with a Zta expression plasmid is the
standard method for reactivating EBV-infected 293 cells into
lytic replication for virus production [3] (Table 1). Exogenous
expression of Rta can also reactivate EBV out of latency in
some cell lines [31,32]. To determine whether ZVmt-infected
293 cells might be more susceptible to Rta induction than
WT-infected ones because of partial derepression of Zp, we
transfected them in parallel with a weak Rta expression
plasmid, pEBV-RIE [31]. Both the WT- and ZVmt-infected
293 cell lines produced infectious virus following exogenous
addition of Rta (Table 1). However, the virus titers obtained
from the three ZVmt-infected cell lines were approximately
Figure 4. Production of Infectious Virus from the Latently Infected 293 Cell Lines Studied Here
(A) Green Raji units (GRUs) assay showing production of infectious virus from 293-ZVmt cell line 1, but not 293-WT cell line 1. The EBV virus released into
the medium was concentrated by centrifugation and used to infect Raji cells. Fields of Raji cells were examined with visible light (visible) for total cell
number versus ultraviolet light (UV) for EBV-infected, GFP-positive cells.
(B) EBV termini assay for presence of linear and circular episomal EBV genomes. Plasmid DNA was isolated from 293-p2089-WT cell line 1 and 293-ZVmt
cell line 1, cleaved with BamHI restriction endonuclease, separated by electrophoresis in a 0.8% agarose gel, transferred to a Hybond-N membrane (GE
Healthcare), andprobedwith anEBV probe specificto the endsof theEBV genome[30]. Thesize markersindicatedon the rightconsistedof a DNAladder
(New England Biolabs) run in the same gel. The positions of circular EBV genomes with fused termini and linear EBV genomes are indicated on the left.
doi:10.1371/journal.ppat.0030194.g004
Table 1. Spontaneous and Induced Reactivation of Wild-Type
and ZV Mutant EBV in 293 Cells (GRU/ml)
Treatment Wild-Type Cell Line ZV Mutant Cell Line
123123
None ,0.1 ,0.1 ,0.1 1 3 10
2 1 3 10
2 2 3 10
2
Zta 1 3 10
4–1 3 10
5a 1 3 10
4–1 3 10
5a
Rta 5 3 10
1 3 3 10
1 5 3 10
1 1 3 10
3 3 3 10
3 6 3 10
2
TPA ,0.1 ,0.1 ,0.1 1 3 10
2 7 3 10
1 8 3 10
1
Butyrate ,0.1 ,0.1 ,0.1 4 3 10
2 2 3 10
2 3 3 10
2
TPAþButyrate ,0.1 ,0.1 ,0.1 1 3 10
3 3 3 10
3 1 3 10
3
Virus titer in the culture medium was determined by a Raji cell assay. Except for cells over-
expressing Zta, media were concentrated prior to the assay.
aData shown are ranges from multiple experiments performed on independent occasions.
doi:10.1371/journal.ppat.0030194.t001
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cell lines. Immunoblot analysis indicated that these pEBV-
RIE-transfected cells contained similar levels of Rta protein
(data not shown). Thus, the signiﬁcant difference in virus
production was probably due to differences in endogenous
expression of the BZLF1 gene given that Zta and Rta function
together in reactivation to lytic replication [33].
TPA and sodium butyrate are two well-known chemical
inducers of latently infected B-lymphocytes. However, their
presence, either individually or in combination, is not
sufﬁcient to reactivate the EBV B95.8 strain out of latency
in 293 cells (M. Altmann and W. Hammerschmidt, personal
communication; Table 1). Nevertheless, treatment of the
ZVmt-infected 293 cell lines with these two chemicals in
combination led to an additional ;10-fold increase in
production of infectious virus over the spontaneous rate
observed with these cell lines (Table 1). Therefore, these two
inducers synergized with the ZV mutation to yield a
signiﬁcantly higher frequency of reactivation of EBV than
any of these three factors could accomplish by themselves or
pairwise. Thus, TPA and sodium butyrate are probably
primarily affecting positive and negative regulatory factors
other than ZEB1 that also play roles in regulating Zp activity
(e.g., c-Jun, MEF2D). Reduction in ZEB1 binding to Zp, in
combination with changes in these other regulators, is
necessary to efﬁciently reactivate EBV to lytic replication in
293 cells. However, ZEB1 is a key, essential regulator since the
ZV mutation, by itself, led to some reactivation, while
treatment with TPA plus butyrate failed to lead to any virus
production in WT-infected 293 cells.
Effect of ZV Mutation on Zp Expression in BJAB Cells
BJAB is a human Burkitt’s lymphoma cell line that can be
efﬁciently infected by the B95.8 strain, with the EBV genome
usually maintained as an episome [34,35]. To study whether
our 2-bp substitution mutation in the ZV element also led to
derepression of Zp in B-cells, we infected BJAB cells in
parallel with WT and ZVmt virus. Hygromycin-resistant, GFP-
positive clones were isolated and grown into cell lines. EBV
DNA was isolated from each cell line and tested as described
above by Southern blot analyses for (i) maintenance as an
episome, (ii) average copy number per cell, and (iii) absence
of gross sequence rearrangements (Figure 5A; data not
shown). Two independent lines each of WT- and ZVmt-
infected BJAB cells with similar episomal copy number were
selected for further study.
As observed in 293 cells, the ZVmt-infected BJAB cell lines
accumulated at least 10-fold more Zta mRNA than the WT-
infected ones (Figure 5B, lanes 2 and 4 vs. lanes 1 and 3).
Treatment of the mutant-infected cells with either TPA or
sodium butyrate led to an additional 5- to 10-fold accumu-
lation of Zta mRNA; treatment in combination led to a
synergetic, 15- to 20-fold increase in accumulation (Figure
5C, lanes 5–8). On the other hand, treatment of the WT-
infected BJAB cells with either TPA or sodium butyrate did
not signiﬁcantly affect accumulation of Zta mRNA; rather,
signiﬁcant activation of the WT promoter was only observed
when these cells were treated concurrently with both
inducers (Figure 5C, lane 4 vs. lanes 1–3). Immunoﬂuor-
escence staining showed that Zta-positive and Rta-positive
cells were readily detectable in the ZVmt-infected BJAB cell
lines with or without TPA treatment, but not in the WT-
infected BJAB cell lines (Figure 5D; Table 2).
Synthesis of Zta protein in the ZVmt-infected BJAB cells
led to derepression of Rp, with signiﬁcant synthesis of both
Rta mRNA (Figure 5C, lane 1 vs. lane 5) and protein (Figure
5D) as well. Nevertheless, we failed to detect linear EBV DNA
termini indicative of packaging of replicated viral DNA into
virion particles in the ZVmt-infected BJAB cell lines (Figure
5A). However, given that neither over-expression of Zta nor
treatment with chemical inducers leads to lytic replication in
WT-infected BJAB cells [35], failure of the ZVmt-infected
BJAB cells to undergo a complete lytic cycle of infection was
expected. Regardless, we conclude that the 2-bp substitution
mutation in the ZV element led to signiﬁcant derepression of
Zp in B-lymphocytic BJAB cells, with the ZVmt-infected BJAB
cells being signiﬁcantly more susceptible to additional
induction of Zp by TPA and sodium butyrate than the WT-
infected BJAB cells. These ﬁndings are very similar to the
ones obtained with the WT- versus ZVmt-infected 293 cell
lines (Figures 2 and 3; Table 1).
ZEB1 Binds the ZV Element of Zp In Vivo
We performed quantitative chromatin immunoprecipita-
tion (ChIP) assays to test directly whether ZEB1 is associated
with Zp via the ZV element in 293 cells latently infected with
EBV. Chromatin was isolated from formaldehyde-ﬁxed 293,
WT-infected 293, ZVmt-infected 293, and 293 cells infected
with the wild-type revertant of the ZV mutant, ZVmtRev. The
chromatin was sheared by sonication to fragments with an
average length of ;500 bp, and subjected to immunopreci-
pitation with a ZEB1-speciﬁc antibody. DNA extracted from
the precipitated chromatin was used as template for quanti-
tative PCR ampliﬁcation with a pair of primers speciﬁc for Zp.
As positive and negative controls, the PCR ampliﬁcation was
also performed with pairs of primers speciﬁc for (i) Rp, which
also contains a ZEB1-binding site [18], (ii) the interleukin 2
promoter (IL-2p), a cellular promoter with a known ZEB1-
binding site [36], and (iii) an EBV sequence located 4.8-kbp
upstream of the Zp transcription initiation site. The ZV
mutant exhibited a 2- to 3-fold reduction in ZEB1 binding to
Zp compared with the parental WT and the revertant, i.e., the
2-bp mutation reduced but did not abolish ZEB1 binding
(Figure 6A, lane 3 vs. lanes 2 and 4; see Figure 6B for
quantitation). This ﬁnding was expected given our recent
identiﬁcation of a second consensus ZEB1-binding element in
Zp, named ZV’, located at ntþ5 throughþ10 relative to the Zp
transcription initiation site (Figure 1A; Yu, Wang, and Mertz,
unpublished data). Also as expected, the ZV mutation had no
effect on binding of ZEB1 to either Rp or IL-2p (Figure 6A,
Table 2. Percent Latently Infected BJAB Cells Synthesizing Zta
and Rta Protein Spontaneously and After TPA Induction
Cell Line: Wild-Type ZV Mutant
12 1 2
TPA:   þ   þ  þ þ
Protein: Zta ,0.1 ,0.1 ,0.1 ,0 . 1 4637
Rta ,0.1 ,0.1 ,0.1 ,0 . 1 3758
Data shown are means from experiments performed on three independent occasions.
doi:10.1371/journal.ppat.0030194.t002
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ZEB1 Regulation of EBVlane 3 vs. lanes 2 and 4; Figure 6B), and the assay was speciﬁc
for ZEB1 antibody (Figure 6D) and DNA containing a ZEB1-
binding site (Figure 6E). Thus, we conclude that the ZV
element of Zp is a functional ZEB1-binding site. When ZEB1 is
present in cells, it binds concurrently with very high afﬁnity to
both the ZV and ZV’ elements of Zp via its two zinc-ﬁnger
domains [37], thereby maximally silencing expression of the
BZLF1 gene to ensure latency is maintained. Mutation of the
ZV element weakens binding of ZEB1 to Zp, enabling
occasional transcription initiation from Zp and, thus, syn-
thesis of Zta mRNA and protein, leading to reactivation and
thesubsequent cascade of events that result inlytic replication
with synthesis of infectious virions.
Discussion
We examined here the effects of mutating the ZV element
of Zp on maintaining latency and reactivating EBV in
Figure 5. Effect of ZV Mutation in B cell Burkitt’s Lymphoma BJAB Cells
(A) Southern blot analysis of EBV DNA termini present in BJAB-WT and BJAB-ZVmt cell lines.
(B) Northern blot analysis of Zta mRNA accumulated in BJAB cell lines latently infected with WT and ZVmt EBV.
(C) Northern blot analysis of Zta and Rta mRNAs accumulated in BJAB-WT cell line 1 and BJAB-ZVmt cell line 1 following treatment with TPA or sodium
butyrate as indicated for 48 h. The bands corresponding to Zta, Rta, and b-actin mRNAs are indicated on the right.
(D) Immunofluorescence staining of BJAB-WT cell line 1 and BJAB-ZVmt cell line 1 for presence of Zta and Rta proteins. Cells were harvested and fixed
48 h after incubation in the absence or presence of TPA. Fields of cells were photographed with different filters to show the total EBV-positive ones
(GFP) versus the subset of those containing the indicated EBV-encoded Zta and Rta proteins in the upper and lower panels, respectively.
doi:10.1371/journal.ppat.0030194.g005
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ZEB1 Regulation of EBVepithelial and BL cell lines. This is the ﬁrst report of a
systematic analysis of the role of a cis-acting transcriptional
regulatory element of EBV within the context of a whole
genome. We show that a 2-bp substitution mutation in the ZV
element can have dramatic effects on the EBV life cycle.
While this particular ZV mutant established latency in
epithelial 293 cells at a frequency similar to WT EBV, it was
defective in maintaining this latency. All three of the ZV
mutant-infected cell lines we examined in detail sponta-
neously synthesized Zta mRNA and protein at levels sufﬁcient
to reactivate the virus into its lytic cycle, with synthesis of Rta,
early proteins including BMRF1, late proteins including
gp350, linear viral genomes, and infectious virus (Figures 2–
4; Table 1). Neither we nor anyone else to the best of our
knowledge has ever observed spontaneous reactivation of the
WT B95.8 strain of EBV in laboratory-infected 293 cells. We
also did not observe any spontaneous reactivation in 293 cells
infected with the WT revertant of the ZV mutant (Figure 2C;
data not shown). Strikingly, the ZV mutant-infected cell lines
were also more susceptible to induction by either (i) over-
expression of Rta, or (ii) treatment with TPA and sodium
butyrate (Tables 1 and 2; Figure 5C). Quite likely, the
phenotype of the ZEB1-binding site mutant would have been
even more dramatic if the ZV element mutation had been
combined with a ZV’ element mutation to further reduce or
completely eliminate ZEB1 binding to Zp. Furthermore,
preliminary data indicate that the ZV mutant virus is at least
an order-of-magnitude defective relative to WT EBV in
establishing colonies of proliferating lymphocytic cells
following infection of primary human B cells (Yu and Mertz,
Figure 6. Quantitative ChIP Assay Showing Reduced Binding of ZEB1 to Zp in ZVmt-Infected 293 Cells
(A) Autoradiogram of radiolabeled PCR products resolved by electrophoresis in a 2.5% agarose gel. Lanes 1–4, DNA templates were obtained from
chromatin isolated from 293, 293-WT, 293-ZVmt, and 293-ZVmtRev cells immunoprecipitated with a ZEB1-specific antibody; and lanes 5–8, DNA
templates were obtained from input DNA isolated from these cells prior to immunoprecipitation. The percent of the DNA sample used in each PCR
amplification reaction is indicated on the right.
(B) Summary of quantitative analysis of results of ChIP assays performed as shown in panel (A) on three separate occasions starting with cells harvested
on different days. Data were normalized to the amount of PCR product obtained from 293-WT ChIP DNA and shown as means plus standard errors of
the means.
(C) Amplification of 1–2 ll of ChIP DNA by 25 cycles of PCR yields products in the linear range of the assay. The insert shows the autoradiogram of PCR
products obtained starting with 1.0, 1.5, and 2.0 ll of ChIP DNA and the primers for Zp.
(D) Autoradiogram of PCR products of DNA templates obtained by immunoprecipitation of chromatin from 293 and 293-WT cells with antibody to ZEB1
(lanes 1 and 2) versus pre-immune rabbit IgG (lanes 3 and 4).
(E) Autoradiogram of PCR products from DNA templates obtained from chromatin immunoprecipitated with ZEB1 antibody (lanes 1 and 2) or input
DNA isolated prior to immunoprecipitation (lanes 3 and 4) using a pair of primers corresponding to a region of EBV located 4.8-kbps upstream of the Zp
transcription initiation site that lacks a ZEB1-binding site. The 190-bp PCR product is indicated by an arrow.
doi:10.1371/journal.ppat.0030194.g006
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ZEB1 Regulation of EBVunpublished data). Thus, we conclude that the ZV element is a
key component of Zp, playing a central role in regulating the
switch in the EBV life cycle between latency and lytic
replication.
We have recently published in collaboration with the
Kenney laboratory that exogenous addition of ZEB1 represses
Zp activity from both a Zp reporter plasmid and whole EBV
genomes in gastric carcinoma ZEB1-negative AGS cells that
are normally highly lytic for EBV [38]. Taken together with
previously published data showing that numerous different
mutations in the ZV element exhibit a similar effect on Zp
activity in a transient transfection reporter assay [16,18], this
ﬁnding provides strong evidence that the phenotype of the
ZV mutant studied here is, indeed, due to it altering ZEB1
binding rather than fortuitously creating a binding site for
another transcription factor.
Our ﬁnding that the ZV mutant can establish a latent form
of infection in 293 cells rather than being a constitutive lytic
mutant suggests that, although the ZEB1-binding ZV element
is a physiologically important silencer of Zp, other negative
regulatory elements (e.g., ZEB1-binding ZV’ element, MEF2D-
binding ZI elements, ZIIR element [14]) also contribute to the
very tight repression of Zp observed in 293 cells. In addition,
for efﬁcient reactivation of EBV from latency into lytic
replication, positive transcriptional regulatory factors (e.g.,
ZII-binding proteins such as ATFs, CREBs, and AP-1) are
required as well. Thus, while ZEB1 binding to Zp plays a
central role in regulating EBV’s switch between latency and
lytic replication, it functions in coordination with other
cellular regulators of Zp to determine whether the BZLF1
gene is expressed in a speciﬁc cell type under speciﬁc growth
conditions. Consistent with this conclusion, we have recently
published in collaboration with the Kenney laboratory data
that indicate the following: (i) ZEB1 levels range from very
high to moderate to absent among a variety of epithelial and
B-cell types that are physiologically relevant to EBV; (ii) The
correlation between ZEB1 abundance and whether infection
by EBV is latent or lytic is fairly good, but far from perfect;
and (iii) The abundance of activated c-Jun also contributes to
how a cell responds to EBV infection [38]. In addition, loss of
Zp repression via ZEB1 binding to the ZV/ZV’ elements might
also occur via changes in ZEB1 interactions with cellular co-
regulators leading to ZEB1, itself, switching from a repressor
binding CtBPs to an activator binding Smads, p300, and other
co-activators [39].
Sodium butyrate inhibits the activity of histone deacetylase
complexes (HDACs), leading to acetylation of histone
proteins and, subsequently, promoters becoming more
accessible to transcriptional activators and the cellular
transcription machinery [40]. TPA is a multi-functional
inducer. It activates the cellular protein kinase C pathway
in B cells [41], inducing phosphorylation of Zta protein [42]
which can then activate Rp [43] leading to synthesis of Rta
protein and subsequent activation of Zp [44]. Nevertheless,
treatment of WT-infected 293 cell lines with TPA plus sodium
butyrate fails to induce reactivation of EBV (e.g., Table 1). In
contrast, identical treatment of the ZVmt-infected 293 cell
lines led to a 10-fold increase in virus production above that
observed spontaneously (Table 1). Thus, high-afﬁnity binding
of ZEB1 to the ZV/ZV’ elements of Zp directly over the
transcription initiation site is sufﬁcient to maintain repres-
sion of the BZLF1 gene expression in 293 cells even when
inducers make Zp much more accessible to its positive
regulators. With the 2-bp mutation in the ZV element studied
here partially alleviating binding of ZEB1 to Zp (Figure 6), the
addition of these inducers increased the probability that
transcription from Zp would reach the threshold level at
which Zta protein was produced in sufﬁcient quantity to
irreversibly activate transcription from Zp and Rp, leading to
full-blown reactivation with lytic replication.
Binding of ZEB1 to Zp was also found to be important in B
cells. Zp expression was tightly repressed and not inducible
by either TPA or sodium butyrate in the WT-infected B-
lymphocytic BJAB cells. Only treatment of the WT-infected
BJAB cells with both inducers in combination led to
signiﬁcant accumulation of Zta mRNA (Figure 5C). On the
other hand, Zp was spontaneously expressed in the ZV
mutant-infected BJAB cells. Moreover, either TPA or sodium
butyrate was sufﬁcient to further activate Zp expression, with
signiﬁcant accumulation of Rta as well as Zta mRNA,
presumably due to Zta protein activating Rp expression.
Unfortunately, since BJAB cells do not support EBV late gene
expression and viral DNA replication, up-regulation of Zp
and Rp in the mutant-infected BJAB cells did not lead to
production of infectious virus. Nevertheless, our recent
preliminary ﬁnding that the ZV mutant virus is at least an
order-of-magnitude defective relative to the parental WT
EBV in establishing colonies of proliferating lymphocytic
cells following infection of primary human B cells (Yu and
Mertz, unpublished data) provides strong evidence that ZEB1
binding to the ZV element of Zp is, indeed, important for
establishing a stable latent infection in B cells as well as
epithelial cells.
We found that the ZV mutant exhibited only a 2- to 3-fold
reduction in ZEB1 binding to Zp (Figure 6), yet a 20-fold or
more increase in accumulation of Zta mRNA and protein
(Figures 2 and 5). These two sets of data are quite compatible
given the fact that a small initial increase in expression of the
BZLF1 gene in the context of cells infected with whole EBV
genomes can lead to a large change in expression because Zta
protein activates expression of the BRLF1 gene, with the Rta
protein then up-regulating BZLF1 gene expression to high
levels. These ﬁndings also provide an explanation for why we
chronically observe a small percentage of the ZVmt-infected
293 cells to have spontaneously reactivated into full-blown
EBV lytic replication while most of the cells in the population
still score as Zta-negative in our IFS assay (Figure 3), i.e., once
a cell manages to synthesize Zta mRNA and protein above a
critical threshold level, it irreversibly switches into the lytic
cycle. On the other hand, transcription of Zp remains tightly
repressed in the WT-infected 293 cells, with infectious virus
never produced without exogenous addition of Zta or Rta
(e.g., Table 1).
Amon et al. [45] noted little difference by immunoblot
analysis between wild-type and the 2-bp ZV mutant of Zp
studied here in BZLF1 gene expression before versus after
anti-Ig induction in Akata cells. This seeming discrepancy
with our results could be due to epigenetic (e.g., methylation
status of Zp) or structural (e.g., Zp’s distance from OriP)
differences between the p2089 bacmid used by us and the
mini-EBV plasmid used in their study. Alternatively, their use
of more sensitive assays (e.g., qRT-PCR, different method for
extraction and detection of Zta protein) likely would have
revealed that the ZV mutant actually did over-express Zp,
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earlier times after anti-Ig induction, consistent with the large
difference in Zp expression they had reported earlier
between wild-type and the ZV mutant using a luciferase
reporter assay [24].
In summary, we show that a mere 2-bp substitution
mutation in the ZEB1-binding site in Zp in the context of a
whole EBV genome can lead to expression of EBV IE, E, and L
genes and production of infectious virus under conditions in
which the B95.8 strain of WT EBV has never been observed to
reactivate out of latency. Given this ﬁnding, we speculate that
loss of ZEB1 binding to Zp as a repressor by (i) mutation of the
ZV’ as well as the ZV element of Zp, (ii) knock down of
synthesis of ZEB1 in the host cell, or (iii) switching ZEB1 from
a repressor to activator of transcription (e.g., via TGF-b
signaling of Smads [39]) could lead to efﬁcient reactivation
into lytic EBV replication in latently infected cells, especially
if combined with loss as well of other repressors of BZLF1
gene expression (e.g., MEF2D, the ZIIR element-binding
protein) and activation of transcriptional activators (e.g.,c -
Jun). Thus, ZEB1 is a novel candidate target for lytic-induction
therapies for some EBV-associated malignancies [46]. In
addition, an EBV strain containing mutations in the ZV/ZV’
elements in combination with a mutation in another negative
regulatory element of Zp (e.g., ZIIR) may provide the basis for
development of a constitutively lytic strain of EBV that could
serve as a vaccine for immunization against EBV infection.
Materials and Methods
Cells and plasmids. 293, a human embryonic kidney cell line, was
obtained from W. Hammerschmidt. Raji and BJAB are EBV-positive
and -negative human BL cell lines, respectively. They were main-
tained at 37 8C in RPMI1640 medium supplemented with 10% fetal
bovine serum (FBS).
Plasmid pCMV-BZLF1 [47], encoding Zta protein, and plasmid
p154.13, containing nt ;101,000 through ;113,000 of EBV strain
B95.8, were obtained from B. Sugden. Plasmid p2089 [25], containing
the complete genome of EBV B95.8 strain, and plasmid p2670 [26],
encoding EBV glycoprotein gp110, were obtained from W. Ham-
merschmidt. Plasmid pGS284, containing an ampicillin cassette and
the levansucrase gene for positive and negative selection, respec-
tively, and E. coli strains GS500 (RecAþ) and S17kpir [48] were
provided by S. Speck. Plasmid pEBV-RIE [31], encoding Rta protein,
was obtained from S. Kenney. Plasmids containing the XhoI and EcoRI
subfragments of EBV for termini assays were provided by N. Raab-
Traub [30].
Mutagenesis of p2089. The 2-bp substitution mutation, ZVmt, was
introduced into the Zp ZV element in p2089 by allelic exchange in E.
coli as described by Smith and Enquist [49] and Moorman et al. [48].
Brieﬂy, the mutation was generated by a two-step, PCR-based site-
directed mutagenesis of plasmid p154.13. A 1,100-bp EBV DNA
fragment containing the mutated ZV element near its center was
cloned into pGS284 and transformed into S17kpir by electroporation
(Bio-Rad). Plasmid p2089 was transformed by electroporation into
GS500. The resulting S17kpir and GS500 cells were mated.
Integration of pGS284 into p2089 and its subsequent excision via
homologous recombination were sequentially selected using the
markers present in these two plasmids. PCR screening indicated 5%
of the p2089 revertants had lost the WT Zp and retained the ZVmt
one. The desired mutation in p2089 and nowhere else throughout the
entire BZLF1 promoter region was conﬁrmed by DNA sequence
analysis. The p2089-ZVmt clones were also digested with a variety of
restriction enzymes including EcoRI, BamH1, HindIII, and SaII. Only
ones with digestion patterns identical to the parental p2089 were
retained. A wild-type revertant of p2089-ZVmt, p2089-ZVmtRev, was
constructed by mutagenesis of p2089-ZVmt and thoroughly charac-
terized likewise.
Isolation of WT- and ZVmt-infected 293 and BJAB cell lines. The
p2089-WT and p2089-ZVmt DNAs were puriﬁed by equilibrium
centrifugation in CsCl-ethidium bromide gradients, introduced into
293 cells with Lipofectamine 2,000 (Invitrogen), and selected by
incubation in the presence of 100 lg/ml hygromycin as described by
Neuhierl et al. [26]. GFP-positive colonies were picked 4- to 6-weeks
later and grown into cell lines. To make virus stocks, these EBV-
infected cells were co-transfected with pCMV-BZLF1 (5 lg/100-mm
dish) and p2670 (5 lg/100-mm dish) using Lipofectamine 2000. The
culture medium was harvested 72 h later, passed through a 0.8-lm
ﬁlter, and stored at 4 8C.
BJAB cells were infected with WT and ZV mutant virus stocks at a
multiplicity of infection of 0.1 GRUs per cell as described by Marchini
et al. [35], plated at 100 cells per well in 96-well plates, and grown in
the presence of 300 lg/ml hygromycin until GFP-positive colonies
emerged. The EBV genomes in each of the numerous 293 and BJAB
cell lines were extensively characterized by DNA sequence analysis of
the entire BZLF1 promoter region and restriction fragment patterns
as described above.
Northern and Southern blot analyses. Whole-cell polyadenylated
RNA was isolated with oligo(dT) cellulose [50]. In Figure 5C, mRNA
was harvested after incubation of the cells with TPA and sodium
butyrate for 48 h. Northern blot analysis was performed as previously
described [51]. Radiolabeled probes were prepared using a random
primer labeling system (Amersham). A 311-bp fragment from ntþ8t o
þ318 relative to the Zp transcription initiation site, generated by
PCR, was used as template for making the probe for detection of both
Zta and Rta mRNAs. A 177-bp human b-actin fragment [52], a gift
from S. Guang, was used as template for making a b-actin probe.
Southern blot analysis was performed as previously described [53].
The p2089 DNA was digested with BamHI prior to electrophoresis in
a 0.8% agarose gel. Plasmid p154.13 was used as template for making
a probe that detects EBV’s BamHI fragments Z, R, K, and B. EBV
termini assays were performed as previously described [30].
Immunoblot analyses and IFS. To detect Zta, Rta, and BMRF1
proteins by immunoblotting, cells in 100-mm dishes were lysed in
SUMO lysis buffer [54]. EBV proteins were separated by SDS-12%
PAGE and detected by incubation with monoclonal anti-Zta (Argene,
1:200 dilution), anti-Rta (Argene, 1:100 dilution), anti-BMRF1
(Capricorn, 1:100 dilution), or anti-b-actin (Sigma, 1:5000 dilution)
antibodies, followed by incubation with goat anti-mouse IgG horse-
radish-conjugated secondary antibody (Pierce, 1:5,000 dilution). The
bound secondary antibody was visualized using a chemiluminescence
kit (Roche). For IFS, the cells were ﬁxed with methanol:acetone (1:1)
for 10 min at room temperature, pre-incubated with phosphate-
buffered saline (PBS) containing 20% FBS, incubated with mono-
clonal anti-Zta (1:40 dilution), anti-Rta (1:40 dilution), anti-BMRF1
(1:40 dilution), or anti-gp350 (Chemicon, 1:100 dilution) antibody,
washed with PBS, incubated with a Texas Red-conjugated, anti-mouse
IgG secondary antibody (Jackson Laboratories, 1:100), washed with
PBS, embedded in mounting medium (Vector Laboratories), and
examined with a ﬂuorescence microscope (Zeiss).
Assays for infectious EBV. To assay for spontaneous reactivation,
latently infected 293 cells were plated in 100-mm dishes and
incubated for 3 days until ;80% conﬂuent. The medium was
harvested, passing through a 0.8-mm ﬁlter, and adjusted to 8 ml
total volume. For chemical induction, the cells were incubated for 48
h with TPA (20 ng/ml), sodium butyrate (3 mM), or both before the
medium was processed as above. For induction with Rta, the cells
were transfected with pEBV-RIE (5 lg per 100-mm dish) with
Lipofectamine 2000. The relative virus titers were determined by a
Raji cell assay, with the number of GFP-positive cells being counted in
a hemocytometer by ultraviolet microscopy [27]. This assay under-
estimates the concentration of infectious virus by a factor of at least
10 [27]. When virus titer was low, the virus particles were
concentrated by centrifugation in an 80Ti Beckman rotor for 2 h
at 17,500 rpm prior to infection of the Raji cells.
ChIP assay. Quantitative ChIP analysis was performed as described
by Aparicio et al. [55]. Brieﬂy, 293 cells latently infected with WT, ZV
mutant, or ZVmtRev along with uninfected 293 cells as a negative
control were ﬁxed with formaldehyde and used to prepare
chromatin. After sonication to shear the chromatin to average size
of ;500 bp, antibody to ZEB1 (Santa Cruz Biotechnology) and
protein A/G plus-agarose beads (Santa Cruz Biotechnology) were
added to immunoprecipitate the ZEB1-containing chromatin. The
beads were collected by centrifugation and washed extensively. The
cross-linked protein-DNA complexes were eluted and heated at 67 8C
to reverse the crosslinking. The resulting DNA was subject to 25
cycles of PCR using the following primers: Zp, forward 59-
TGATGTCATGGTTTGGGA-39, reverse 59-CTGCATGCCATGCA-
TA-39; Rp, forward 59-GGGTGGTGATGTAGCTATAC-39, reverse
59-CCTAGGGATTTCATAAAGGCC-39; IL-2p, forward 59-CTACATC-
CATTCAGTCAGTC-39, reverse 59-AACTCTTGAACAAGAGATGC-
39; and negative control EBV sequence located 4.8-kbp upstream of
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CATCTGGA-39, reverse 59-AACTTGGACGTTTTTGGGGT-39. Con-
trols included the following: (i) The PCR condition used (94 8C 30 sec,
55 8C 30 sec, 72 8C 1 min for 25 cycles) was one experimentally
determined to yield products falling within the linear range of the
assay (Figure 6C); (ii) Normal preimmune rabbit IgG immunopreci-
pitated at most one-ﬁfth of the level of Zp DNA (Figure 6D); and (iii)
ZEB1 antibody failed to immunoprecipitate EBV sequences located
4.8-kbps upstream of the Zp transcription initiation site (Figure 6E).
The PCR products were resolved by electrophoresis in a 2.5%
NuSieve 3:1 agarose gel (Cambrex) and the resulting DNA bands
obtained from three independent sets of experiments were quanti-
ﬁed using a PhosphorImager (Figure 6B).
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